Posted by Michael Wonder on 18 Aug 2022
PHARMAC makes cancer treatment available to more people
18 August 2022 - PHARMAC has confirmed today they are widening access from 1 September 2022 to a targeted cancer treatment, obinutuzumab (Gazyva), for people with indolent non-Hodgkin lymphoma.
PHARMAC had originally intended to widen access to obinutuzumab in combination with bendamustine for people with follicular lymphoma and marginal zone lymphoma that has relapsed after, or is resistant to, a rituximab-containing treatment within 6 months.
